IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Coumarin-Based Molecular Hybrids As Emerging Anti-Inflammatory And Analgesic Agents: A Comprehensive Review

[1]Apeksha O Wasnik, [2]Dr. Sunil S. Menghani, [3]Rashtrapal N. Walde

[1,2,3]Gondia College of Pharmacy, Chulod Road, Gondia Maharashtra,441614

Abstract

Inflammation and pain remain major clinical challenges despite the availability of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and opioid analgesics, which are often associated with adverse effects, tolerance, or limited long-term efficacy. Coumarin, a privileged heterocyclic scaffold widely distributed in natural products and synthetic compounds, has attracted significant interest in medicinal chemistry due to its diverse pharmacological properties, including anti-inflammatory, analgesic, anticoagulant, antimicrobial, and anticancer activities. In recent years, molecular hybridization has emerged as a powerful drug design strategy, wherein two or more pharmacophores are covalently linked into a single molecular entity to enhance biological activity, selectivity, and safety profiles. The integration of coumarin with other bioactive moieties through molecular hybridization has led to the development of novel hybrid molecules with promising anti-inflammatory and analgesic potential. This comprehensive review critically summarizes recent advances in the design, synthesis, structure–activity relationships, and pharmacological evaluation of coumarin-based molecular hybrids targeting inflammatory and pain-related pathways. Emphasis is placed on hybrids incorporating nonsteroidal anti-inflammatory drugs, heterocycles, natural product-derived pharmacophores, and enzyme inhibitors. Mechanistic insights into cyclooxygenase, lipoxygenase, nitric oxide synthase, cytokine modulation, and oxidative stress pathways are discussed. Finally, current challenges, limitations, and future perspectives in the development of coumarin-based hybrid therapeutics are highlighted, providing valuable guidance for future research in inflammation and pain management.

Keywords: Coumarin; Molecular hybridization; Anti-inflammatory activity; Analgesic activity; Medicinal chemistry; Drug design.

1. Introduction

Inflammation and pain are complex biological responses that play essential roles in protecting the body from injury, infection, and harmful stimuli.[1] However, chronic inflammation is associated with numerous pathological conditions such as arthritis, cardiovascular diseases, neurodegenerative disorders, and certain cancers. Conventional anti-inflammatory and analgesic drugs, including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, are widely used to manage these conditions.[2] Despite their therapeutic effectiveness, these drugs are often associated with significant adverse effects such as gastrointestinal irritation, cardiovascular risks, tolerance, and dependency.[3] Consequently, there is an ongoing need to develop safer and more effective therapeutic agents with improved pharmacological profiles.[4] Natural products and their derivatives have long served as a valuable source for drug discovery. Among these, coumarin, a benzopyrone-based natural compound found in many plants, has gained considerable attention due to its wide range of biological activities.[5] Coumarin and its derivatives exhibit diverse pharmacological properties including anti-inflammatory, antioxidant, antimicrobial, anticoagulant, anticancer, and analgesic effects.[6] The structural versatility of the coumarin scaffold allows for extensive chemical modification, making it an attractive template for the development of novel therapeutic agents.[7] In recent years, the concept of molecular hybridization has emerged as a promising strategy in medicinal chemistry. Molecular hybridization involves the combination of two or more pharmacophoric moieties into a single molecular framework to produce hybrid compounds with enhanced biological activity and improved selectivity. This approach aims to integrate the beneficial properties of individual pharmacophores while minimizing undesirable side effects.[8] By targeting multiple biological pathways simultaneously, hybrid molecules may demonstrate superior therapeutic efficacy compared with traditional single-target drugs. Coumarin-based molecular hybrids have therefore attracted growing interest as potential anti-inflammatory and analgesic agents.[9] By combining the coumarin nucleus with other bioactive pharmacophores-such as heterocyclic rings, NSAID fragments, or antioxidant moieties—researchers aim to develop multifunctional compounds capable of modulating various inflammatory mediators.[10] These hybrid molecules have shown promising results in inhibiting key inflammatory enzymes and pathways, including cyclooxygenase (COX), lipoxygenase (LOX), nitric oxide synthase, and pro-inflammatory cytokines. In addition, coumarin hybrids may reduce oxidative stress, which plays a significant role in the progression of inflammatory disorders. [11] Several studies have demonstrated that structural modification of the coumarin nucleus can significantly influence biological activity. Substitutions at different positions on the coumarin ring system may enhance pharmacokinetic properties, increase target affinity, and improve overall therapeutic potential.[12] Furthermore, coumarin hybrids have shown promising results in preclinical studies for reducing inflammation and pain in various experimental models, highlighting their potential as candidates for future drug development.[13] The development of coumarin-based molecular hybrids also aligns with modern drug discovery strategies that emphasize multi-target therapeutics. Since inflammation involves multiple biochemical pathways and mediators,

single-target drugs may not always provide optimal therapeutic outcomes.[14] Hybrid molecules that can simultaneously modulate multiple targets may therefore offer improved efficacy and reduced side effects. In summary, coumarin-based molecular hybrids represent an emerging and promising class of compounds in the search for new anti-inflammatory and analgesic agents. Their structural diversity, broad spectrum of biological activities, and ability to interact with multiple molecular targets make them valuable candidates for further research. Continued investigation into their design, synthesis, and pharmacological evaluation may contribute to the development of safer and more effective treatments for inflammatory and pain-related disorders[15]

2. Coumarin as a Privileged Scaffold in Medicinal Chemistry

Coumarins possess a planar aromatic structure with favorable physicochemical properties, enabling interactions with a wide range of biological targets. Naturally occurring coumarins, such as umbelliferone, esculetin, scopoletin, and warfarin, have long been recognized for their therapeutic relevance.[16]

In the context of inflammation and pain, coumarin derivatives have been reported to inhibit cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, suppress pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukins, modulate nitric oxide (NO) production, and exhibit antioxidant activity.[17] These multifaceted mechanisms make coumarin an ideal core structure for the development of multitarget anti-inflammatory and analgesic agents.[18] The ease of chemical modification at multiple positions of the coumarin nucleus further enhances its utility in drug design. Substitutions at positions 3, 4, 6, 7, and 8 allow fine-tuning of biological activity and pharmacokinetic behavior, facilitating the development of optimized hybrid molecules.[19]

3. Concept of Molecular Hybridization in Drug Design

Molecular hybridization involves the rational combination of two or more bioactive pharmacophores into a single hybrid molecule.[20] This strategy aims to achieve enhanced efficacy through synergistic interactions, reduce adverse effects, and overcome drug resistance. Depending on the design, hybrids may act on a single target with improved affinity or on multiple targets simultaneously.[21]

Hybrid molecules can be classified into linked hybrids, fused hybrids, and merged hybrids, based on the mode of pharmacophore integration. In the case of coumarin-based hybrids, flexible or rigid linkers are often employed to connect the coumarin core with other pharmacologically active moieties, such as NSAIDs, heterocycles, or natural product fragments.[22]

The molecular hybridization approach is particularly attractive for inflammation and pain management, as these conditions involve complex and interconnected signaling pathways.[23] Multitarget hybrids may provide superior therapeutic outcomes compared to single-target agents.[24]

4. Coumarin–NSAID Hybrid Molecules

One of the most extensively explored categories of coumarin-based hybrids involves the conjugation of coumarin with NSAIDs such as ibuprofen, diclofenac, naproxen, and indomethacin.[25] These hybrids are designed to retain COX inhibitory activity while potentially reducing gastrointestinal toxicity associated with traditional NSAIDs.[26]

Several coumarin–NSAID hybrids have demonstrated significant inhibition of COX-2 over COX-1, indicating improved selectivity. In vivo studies using carrageenan-induced paw edema and acetic acid-induced writhing models have shown enhanced anti-inflammatory and analgesic effects compared to parent NSAIDs.[27] Additionally, the antioxidant properties of the coumarin moiety may contribute to mucosal protection and reduced oxidative stress.[28]

5. Coumarin–Heterocycle Hybrids

Coumarin hybrids incorporating heterocyclic moieties such as pyrazoles, triazoles, thiazoles, imidazoles, and quinolines have attracted considerable attention. Many of these heterocycles are known for their anti-inflammatory and analgesic properties.[29]

Coumarin–pyrazole hybrids, for instance, have exhibited potent inhibition of pro-inflammatory mediators and significant analgesic activity in animal models.[30] Similarly, coumarin–triazole hybrids synthesized via click chemistry have shown favorable pharmacological profiles, attributed to improved binding interactions with inflammatory targets.[31]

6. Coumarin–Natural Product Hybrids

Hybridization of coumarin with natural product-derived pharmacophores, such as flavonoids, chalcones, curcumin, and cinnamic acid derivatives, represents another promising approach. These hybrids aim to combine the antioxidant and anti-inflammatory properties of natural compounds with the pharmacological versatility of coumarin.[32]

Several coumarin–chalcone hybrids have demonstrated strong inhibition of inflammatory enzymes and cytokines, along with notable analgesic effects.[33] The presence of multiple aromatic rings and conjugated systems enhances radical scavenging activity, contributing to their anti-inflammatory efficacy.[34]

7. Structure–Activity Relationship (SAR) Insights

Structure–activity relationship studies have revealed that the nature and position of substituents on the coumarin nucleus significantly influence anti-inflammatory and analgesic activity.[35] Electron-donating groups at the 7-position often enhance activity, while appropriate linker length and flexibility are critical

for optimal target binding.[36] Hybrid molecules with balanced lipophilicity and hydrogen bonding capacity tend to exhibit superior biological activity and pharmacokinetic profiles.[37] SAR analyses provide valuable guidance for the rational design of next-generation coumarin-based hybrids.[38]

8. Mechanisms of Anti-Inflammatory and Analgesic Action

Inflammation and pain are complex biological processes involving multiple cellular mediators, signaling pathways, and biochemical reactions.[39] The anti-inflammatory and analgesic activities of coumarin-based molecular hybrids are primarily attributed to their ability to modulate key inflammatory mediators, inhibit specific enzymes, and regulate oxidative stress.[40] These mechanisms collectively contribute to the reduction of tissue inflammation and the alleviation of pain.[41]

1. Inhibition of Cyclooxygenase (COX) Enzymes

One of the primary mechanisms by which coumarin-based hybrids exert anti-inflammatory and analgesic effects is through the inhibition of cyclooxygenase enzymes, particularly COX-1 and COX-2.[42] These enzymes play a crucial role in the conversion of arachidonic acid into prostaglandins, which are important mediators responsible for inflammation, pain, and fever. Overexpression of COX-2 is commonly associated with inflammatory conditions.[43] Many coumarin derivatives have demonstrated the ability to selectively inhibit COX-2, thereby reducing the production of prostaglandins without significantly affecting COX-1, which is involved in normal physiological functions such as gastric mucosal protection. This selective inhibition helps decrease inflammation and pain while minimizing gastrointestinal side effects commonly associated with traditional non-steroidal anti-inflammatory drugs.[44]

2. Inhibition of Lipoxygenase (LOX) Pathway

In addition to cyclooxygenase inhibition, coumarin-based molecular hybrids can also interfere with the lipoxygenase (LOX) pathway.[45] LOX enzymes catalyze the oxidation of arachidonic acid to produce leukotrienes, which are potent inflammatory mediators involved in allergic reactions, bronchoconstriction, and inflammatory responses. By inhibiting LOX enzymes, coumarin hybrids reduce the formation of leukotrienes and other inflammatory compounds, thereby suppressing the inflammatory cascade.[46] Dual inhibition of both COX and LOX pathways is considered a highly desirable therapeutic strategy because it targets multiple components of the inflammatory process.[47]

3. Suppression of Pro-Inflammatory Cytokines

Coumarin-based hybrids also modulate the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These cytokines play a significant role in initiating and amplifying inflammatory responses by activating immune cells and promoting the release of additional inflammatory mediators. By suppressing the expression or release of these cytokines, coumarin hybrids can effectively reduce inflammatory signaling and limit tissue damage.[48] This mechanism is particularly important in chronic inflammatory diseases where excessive cytokine production contributes to disease progression.[49]

4. Inhibition of Nitric Oxide Production

Nitric oxide (NO) is another key mediator involved in inflammatory processes. During inflammation, inducible nitric oxide synthase (iNOS) produces large amounts of nitric oxide, which can react with reactive oxygen species to form peroxynitrite, leading to oxidative damage and tissue injury.[50] Several coumarin-based hybrid compounds have shown the ability to inhibit iNOS expression and reduce nitric oxide production in activated macrophages. This reduction in NO levels helps decrease inflammatory responses and contributes to the overall anti-inflammatory activity of these compounds.[52]

5. Antioxidant Activity and Reduction of Oxidative Stress

Oxidative stress plays a significant role in the progression of inflammation and pain. Reactive oxygen species (ROS) generated during inflammatory processes can damage cellular components such as lipids, proteins, and DNA, further aggravating inflammation. Coumarin derivatives possess strong antioxidant properties due to their aromatic structure and electron-donating substituents.[53] These compounds can scavenge free radicals, reduce ROS levels, and protect tissues from oxidative damage. The antioxidant activity of coumarin hybrids therefore complements their anti-inflammatory action by interrupting the cycle of oxidative stress and inflammation.

6. Modulation of Pain Signaling Pathways

In addition to their anti-inflammatory effects, coumarin-based hybrids may directly influence pain perception by modulating nociceptive pathways.[54] These compounds can interfere with pain signaling at peripheral and central levels by reducing inflammatory mediator release, inhibiting nerve sensitization, and modulating ion channels involved in pain transmission.[55] Through the combined effects on inflammatory mediators, enzyme inhibition, cytokine suppression, antioxidant activity, and modulation of nociceptive pathways, coumarin-based molecular hybrids demonstrate significant potential as multifunctional agents for the treatment of inflammatory conditions and pain disorders.[56] Their multi-target mechanisms make them promising candidates for the development of safer and more effective therapeutic agents in modern medicinal chemistry. [57]

7. Challenges and Limitations

Limited Clinical Evidence

Although numerous coumarin-based molecular hybrids have shown promising anti-inflammatory and analgesic activity in in vitro and in vivo studies, most compounds have not yet progressed to clinical trials.[58] The lack of clinical data limits the understanding of their safety, efficacy, and therapeutic potential in humans.[59]

Potential Toxicity and Safety Concerns

Some coumarin derivatives may exhibit hepatotoxicity or other adverse effects when administered at high doses or over prolonged periods. Structural modifications intended to enhance pharmacological activity can sometimes introduce toxicity, making safety evaluation an important challenge in drug development.[60]

Poor Pharmacokinetic Properties

Many coumarin-based compounds suffer from unfavorable pharmacokinetic characteristics such as low solubility, limited bioavailability, rapid metabolism, and short half-life. These factors may reduce their therapeutic effectiveness and require further optimization through medicinal chemistry strategies.

Metabolic Instability

Coumarin derivatives are often susceptible to metabolic degradation by liver enzymes, particularly cytochrome P450 enzymes. Rapid metabolism may reduce the concentration of active compounds in systemic circulation, thereby limiting their pharmacological activity.

Complex Synthetic Procedures

The synthesis of certain coumarin-based molecular hybrids can involve multiple reaction steps, expensive reagents, or low overall yields. Such complex synthetic routes may hinder large-scale production and industrial application.[61]

Target Selectivity Issues

Although molecular hybridization aims to produce multi-target agents, excessive interaction with unintended biological targets may lead to off-target effects. Achieving an optimal balance between multi-target activity and selectivity remains a significant challenge.

Limited Structure–Activity Relationship (SAR) Data

While several studies have explored coumarin derivatives, comprehensive SAR analyses for many hybrid structures are still lacking. This limits the ability to rationally design compounds with improved potency and reduced toxicity.[62]

Regulatory and Developmental Barriers

Drug development requires extensive preclinical and clinical evaluation, regulatory approval, and high financial investment. These challenges can slow the translation of promising coumarin-based hybrids from laboratory research to clinical therapeutics.[63]

Potential Drug–Drug Interactions

Coumarin derivatives may interact with other medications by influencing metabolic enzymes or protein-binding sites, which could alter the pharmacokinetics of co-administered drugs and increase the risk of adverse reactions.[64]

8. Future Perspectives

Coumarin-based molecular hybrids are gaining increasing attention as promising candidates for next-generation anti-inflammatory and analgesic therapies. Future research should emphasize the rational design of hybrid molecules that simultaneously target multiple inflammatory pathways, including cyclooxygenase (COX), lipoxygenase (LOX), and pro-inflammatory cytokines, to achieve enhanced therapeutic efficacy with reduced adverse effects. The integration of advanced computational techniques such as molecular docking, quantitative structure–activity relationship (QSAR) modeling, and artificial intelligence-driven drug discovery can significantly accelerate the identification and optimization of potent lead compounds. Moreover, improving the pharmacokinetic and pharmacodynamic profiles of these hybrids remains a key priority. Strategies such as prodrug design, bioisosteric modification, and incorporation into nanocarrier-based drug delivery systems may enhance solubility, stability, and targeted

delivery, thereby minimizing systemic toxicity. In addition, detailed investigations into structure–activity relationships (SAR) will provide valuable insights for fine-tuning biological activity. Importantly, extensive preclinical and clinical studies are necessary to validate the safety, efficacy, and long-term therapeutic potential of coumarin-based hybrids. Overall, these multifunctional molecules hold significant promise in overcoming the limitations of conventional NSAIDs and advancing the development of safer, more effective anti-inflammatory drugs.

11. Conclusion

Coumarin-based molecular hybrids have emerged as a valuable and innovative class of compounds in the search for improved anti-inflammatory and analgesic agents. By combining the versatile coumarin scaffold with established pharmacophores such as NSAIDs, these hybrids demonstrate enhanced biological activity, multi-target mechanisms, and the potential for reduced adverse effects compared to conventional therapies. Their ability to modulate key inflammatory pathways, including cyclooxygenase (COX), lipoxygenase (LOX), and oxidative stress-related processes, highlights their therapeutic significance. Extensive studies have shown that structural modification of the coumarin nucleus and the nature of the linker play critical roles in determining the pharmacological profile of these hybrids. Advances in medicinal chemistry, along with computational tools, have further facilitated the design and optimization of potent derivatives with improved selectivity and safety. Despite encouraging preclinical findings, challenges such as limited clinical data, potential toxicity, and optimization of pharmacokinetic properties remain. Addressing these issues through systematic research and well-designed clinical trials is essential. In conclusion, coumarin-based molecular hybrids represent a promising strategy for developing safer and more effective anti-inflammatory and analgesic drugs, offering a strong foundation for future therapeutic advancements in inflammation-related disorders.

Reference

1. Abdel Ghany LMA et al. Coumarin–curcumin hybrids targeting TNF-α. J Enzyme Inhib Med Chem. 2023.

2. Atkins P, Shriver D (2010) Shriver and Atkins' inorganic chemistry. Oxford University Press, UK

3. Barnes PJ. Anti-inflammatory drug mechanisms. Pharmacol Rev. 2016.

4. Barsanti PA, Wang W, Ni Z-J et al (2010) The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5. Bioorg Med Chem Lett 20:157–160. https://doi.org/10.1016/j.bmcl.2009.11.012 DOI: 10.1016/j.bmcl.2009.11.012

5. Basumatary G, Dhar ED, Das D, Deka RC, Yadav AK, Bez G (2020) Coumarin-based trisubstituted methanes as potent anthelmintic: synthesis, molecular docking and in vitro efficacy. J Chem Sci 132:1–12. https://doi.org/10.1007/s12039-020-1737-z DOI: 10.1007/s12039-020-1737-z

6. Borad MA, Bhoi MN, Prajapati NP, Patel HD (2014) Review of synthesis of spiro heterocyclic compounds from isatin. Synth Commun 44:897–922. https://doi.org/10.1080/00397911.2013.843196 DOI: 10.1080/00397911.2013.843196

7. Borges F et al. Simple coumarins: privileged scaffolds. Curr Med Chem. 2005.

8. Brough PA, Aherne W, Barril X et al (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51:196–218.

9. Chai G, Brewer JM, Lovelace LL et al (2004) Expression, purification and the 1.8Å resolution crystal structure of human neuron specific enolase. J Mol Biol 341:1015–1021.

10. Chowdhury R, McDonough MA, Mecinović J et al (2009) Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure 17:981–989.

11. Coumarin–benzimidazole hybrids. Med Chem Res. 2018.

12. Coumarin–chalcone hybrids anti-inflammatory. Eur J Med Chem. 2017.

13. Coumarin–hydrazone derivatives anti-inflammatory. Bioorg Chem. 2021.

14. Da Silva JFM, Garden SJ, Pinto AC (2001) The chemistry of isatins: a review from 1975 to 1999. J Braz Chem Soc 12:273–324. https://doi.org/10.1590/S0103-50532001000300002 DOI: 10.1590/S0103-50532001000300002

15. Dandia A, Singh R, Khaturia S, Merienne C, Morgant G, Loupy A (2006) Efficient microwave enhanced regioselective synthesis of a series of benzimidazolyl/triazolyl spiro [indole-thiazolidinones] as potent antifungal agents and crystal structure of spiro[3H-indole-3,2′-thiazolidine]-3′(1,2,4-triazol-3-yl)-2,4′(1H)-dione. Bioorg Med Chem 14:2409–2417.

16. Decker M. Design of multi-target ligands. Curr Top Med Chem. 2011.

17. Feng L-S, Liu ML, Wang B, Chai Y, Hao X-Q, Meng S, Guo H-Y (2010) Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives. Eur J Med Chem 45:3407–3412.

18. Ferreira ESB, Hulme AN, McNab H, Quye A (2004) The natural constituents of historical textile dyes. Chem Soc Rev 33:329–336.

19. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, et al. Gaussian 16, Revision C.01 (2016)

20. Garcia-Saez I, DeBonis S, Lopez R et al (2007) Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. J Biol Chem 282:9740–9747.

21. Gorman MA (1997) The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. EMBO J 16:6548–6558.

22. Gursoy A, Karali N (2003) Synthesis and primary cytotoxicity evaluation of 3-[[(3-phenyl-4(3H)-quinazolinone-2-yl)mercaptoacetyl]hydrazono]-1H-2-indolinones. Eur J Med Chem 38:633–643.

23. Jia M, Zhang W, Zhu J et al (2021) Microglia-specific expression of HEXA and HEXB leads to poor prognosis in glioblastoma patients. Front Oncol 11:685803.

24. Kaan HYK, Ulaganathan V, Rath O et al (2010) structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem 53:5676–5683.

25. Kaan HYK, Weiss J, Menger D et al (2011) Structure−activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5. J Med Chem 54:1576–1586.

26. Kassab S, Hegazy G, Eid N, Amin K, El-Gendy A (2010) Synthesis of 1H-indole-2,3-dione-3thiosemicarbazone ribonucleosides as antibacterial agents. Nucleosides Nucleotides Nucl Acids 29:72–80.

27. Kim ED, Buckley R, Learman S et al (2010) Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core. J Biol Chem 285:18650–18661.

28. Kostova I. Coumarins as inhibitors of HIV reverse transcriptase. Curr Med Chem. 2006.

29. Lawrence T. NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009.

30. Libby P. Inflammatory pathways in disease. Nature. 2002.

31. Lide DR (1991) Handbook of chemistry and physics, 72nd edn. CRC Press, Boca Raton

32. Mark BL, Mahuran DJ, Cherney MM et al (2003) Crystal structure of human β-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol 327:1093–1109.

33. Medzhitov R. Inflammation biology. Nature. 2008.

34. Meunier B. Hybrid molecules in medicinal chemistry. Acc Chem Res. 2008.

35. Morphy R, Rankovic Z. Designed multiple ligands. J Med Chem. 2005.

36. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 16:2785–2791.

37. Nash L, Jessica Sully K, Horn AB (2001) Observations on the interpretation and analysis of sulfuric acid hydrate infrared spectra. J Phys Chem A 105:9422–9426.

38. Nathan C. Points of control in inflammation. Nature. 2002.

39. Nepali K et al. Hybrid molecules in drug development. Eur J Med Chem. 2014.

40. Niveshika VE, Maurya SK et al (2017) The combined use of in silico, in vitro, and in vivo analyses to assess anti-cancerous potential of a bioactive compound from cyanobacterium Nostoc sp.MGL001. Front Pharmacol 8:00873.

41. Oakley AJ, Yamada T, Liu D et al (2008) The identification and structural characterization of C7orf24 as γ-glutamyl cyclotransferase. J Biol Chem 283:22031–22042.

42. Olszewska E, Borzym-Kluczyk M, Rzewnicki I et al (2009) Hexosaminidase as a new potential marker for larynx cancer. Clin Biochem 42:1187–1189.

43. Pai EF, Krengel U, Petsko GA et al (1990) Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. EMBO J 9:2351–2359.

44. Peng XM et al. Coumarin hybrids and pharmacological activities. Med Chem Res. 2013.

45. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612.

46. Quenelle D, Keith K, Kern E (2006) In-vitro and in-vivo evaluation of isatin-β-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res 71:24–30.

47. Ramsay RR et al. Multi-target drug design. Nat Rev Drug Discov. 2018.

48. Riveiro ME et al. Coumarins: pharmacological perspectives. Curr Med Chem. 2010.

49. Ruf A, Rolli V, de Murcia G, Schulz GE (1998) The mechanism of the elongation and branching reaction of Poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol 278:57–65.

50. Same study full article (Taylor & Francis).

51. Sharma P, Baishya T, Gomila RM, Frontera A, Barceló-Oliver M, Verma AK, Das J, Bhattacharyya MK (2022) Structural topologies involving energetically significant antiparallel π-stacking and unconventional N(nitrile)···π(fumarate) contacts in dinuclear Zn(II) and polymeric Mn(II) compounds: antiproliferative evaluation and theoretical studies. New J Chem 46:5296–5311.

52. Sharma P, Gomila RM, Barceló-Oliver M, Verma AK, Dutta D, Frontera A, Bhattacharyya MK (2023) Unconventional dual donor-acceptor topologies of aromatic rings in amine-based polymeric tetrahedral Zn (II) compounds involving unusual non-covalent contacts: antiproliferative evaluation and theoretical studies. Crystals 13:382.

53. Shi M, Zhu J, Wang R et al (2011) Latent TGF-β structure and activation. Nature 474:343–349.

54. Shimizu M et al. Hybrid molecules in drug design. J Med Chem. 2021.

55. Sibuh BZ, Gupta PK, Taneja P et al (2021) Synthesis, in silico study, and anti-cancer activity of thiosemicarbazone derivatives. Biomedicines 9:1375.

56. Singh P et al. Hybrid pharmacophores. Bioorg Chem. 2019.

57. Sridhar SK, Ramesh A (2001) Synthesis and pharmacological activities of hydrazones, Schiff and Mannich bases of isatin derivatives. Biol Pharm Bull 24:1149–1152.

58. Sridhar SK, Saravanan M, Ramesh A (2001) Synthesis and antibacterial screening of hydrazones, Schiff and Mannich bases of isatin derivatives. Eur J Med Chem 36:615–625.

59. Sriram D, Yogeeswari P, Basha JS, Radha DR, Nagaraja V (2005) Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 13:5774–5778.

60. Sriram D, Yogeeswari P, Myneedu NS, Saraswat V (2006) Abacavir prodrugs: microwave-assisted synthesis and their evaluation of anti-HIV activities. Bioorg Med Chem Lett 16:2127–2129.

61. Stefanachi A et al. Coumarin derivatives in medicinal chemistry. Eur J Med Chem. 2018.

62. Strober W (2015) Trypan blue exclusion test of cell viability. Curr Protoc Immunol 111:A3.B.1–A3. B.3.

63. Tennant JR (1964) Evaluation of the trypan blue technique for determination of cell viability. Transplantation 2:685–694.

64. Vachan BS, Karuppasamy M, Vinoth P, Vivek Kumar S, Perumal S, Sridharan V, Carlos Menéndez J (2020) Proline and its derivatives as organocatalysts for multi- component reactions in aqueous media: synergic pathways to the green synthesis of heterocycles. Adv Synth Catal 362:87–110.